

Title: The Changing Global Epidemiology of Re-emerging Human Monkeypox Virus Infection: A Systematic Review

Author's Information

1. Sunder Sham, MBBS, Northwell Health Lenox Hill Hospital, Department of Pathology and Laboratory Medicine, New York, NY
2. FNU Sapna, MBBS, MD, Montefiore Medical center, The University Hospital for Albert Einstein School of Medicine, Bronx, NY
3. FNU Anjali, MBBS, Sakhi Baba General Hospital & Maternity Home, Pano Akil, Pakistan
4. Sanjay Kumar, MBBS, FCPS, Bahria University of Health Sciences Karachi, Pakistan
5. Vivek Podder, MBBS, Bangladesh Institute of Research and Rehabilitation for Diabetes Endocrine and Metabolic Disorders (BIRDEM) Dhaka, Bangladesh
6. Soumya Jaladi, MBBS, University of Louisville, Louisville, KY
7. Ahmed Bendari, MBBCh, Northwell Health Lenox Hill Hospital, Department of Pathology and Laboratory Medicine, New York, NY
8. Reham Al-Refai, MD, Northwell Health Lenox Hill Hospital, Department of Pathology and Laboratory Medicine, New York, NY
9. Manal Mohammad Baloch Bahria University of Health Sciences Karachi, Pakistan
10. Mohammed Abdelwahed, MD, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Pathology and Laboratory Medicine Uniondale, New York
11. FNU Kiran, MD, MPH, Staten Island university hospital, Northwell health, staten Island, New York
12. Hansini Laharwani, MD, Washington University, St. Louis, MO

Corresponding author:

Sunder Sham, MBBS

Northwell Health Lenox Hill Hospital, Department of Pathology and Laboratory Medicine

100 East 77th Street, New York, NY, 10075

Email: drsundersham@gmail.com

Telephone: +1(332) 201 8503

Abstract

Background

Human monkeypox (MPXV) virus infection, an emerging zoonotic disease caused by an orthopoxvirus, leads to smallpox-like disease. Human MPXV infection was first reported in 1970 in the Democratic Republic of Congo (DRC). Before April 2022, MPXV cases were endemic and seldom reported outside African regions; but recent global outbreaks of MPXV are concerning. We aimed to investigate the epidemiology of emerging human monkeypox virus infection including the number of suspected, confirmed, and fatal cases as well as risk factors for contracting monkeypox infection.

Design

We performed a systematic review of peer-reviewed literature by following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. An electronic database search (PubMed, online Willey library, science direct) was undertaken. For monkeypox related studies, we included 25 peer-reviewed articles from 2018 and 2022 and data were extracted to inform current evidence on the cases and public health risk factors for developing infection, and public health advice.

Results

Our reports show a rapid rise of MPVX cases in highly endemic African regions after the 1970s, spread to other countries, and increased median age from young children to young adults. Cessation of smallpox vaccination might be one of the factors responsible for the findings. Till 2022 genomic sequences of ten MPXV strains, associated with the recent countrywide outbreak, have been determined. While West African Clade is mostly implicated in the recent viral surge, data were insufficient to determine which mutation contributed to increased transmissibility. In DRC, sleeping on the floor was significantly (odds ratio [OR] 6.1, 95% confidence interval [CI] 1.2-31.6) associated with contracting MPVX *while eating or processing animal foods was not a significant risk factor*. In the United States, cleaning cages, bedding sick animals (OR 5.3, 95% CI 1.4-20.7), or touching infected animals (OR 4.0, 95% CI 1.2-13.4), daily sick animal exposure (OR 4.0, 95% CI 1.2-13.4) were associated with contracting MPVX infection.

Conclusion

Recent global outbreaks, the rising incidence in young adults and endemic zones might result from smallpox vaccine cessation. Increased risk with sick animal exposure or sleeping on the floor suggests high infectivity from animal excretions. Increasing awareness, strict surveillance, and contact tracing can contain global outbreaks. Ring vaccination approach to exposed people can also be a strategy. Future studies should investigate to determine measures for rapid laboratory diagnosis, maintaining lab safety, and also transmissibility.

Introduction

As the world surpasses the shock of COVID-19 pandemic and learns lessons from the global health failures to control the global outbreak, new infectious diseases threats emerge such as human monkeypox (MPXV) virus infection. [1] Since May 7, 2022, the global health authorities were surprised to experience the unprecedented and unexpected MPVX outbreaks across Europe, the US, and Australia, which have continuously been reported in 12 WHO member states across three WHO regions. [1] MPXV infection, an emerging zoonotic disease caused by an orthopoxvirus, results in a clinically less severe smallpox-like disease. With the smallpox eradication in 1980 with subsequent cessation its vaccination, MPXV has emerged as the most concerning orthopoxvirus for public health [2]. In 1970, MPXV was first identified in a 9-month-old boy in the Democratic Republic of the Congo (DRC), where smallpox had been eliminated in 1968. Before April 2022, MPXV cases were endemic and seldom reported outside African regions where it primarily occurred in central and west Africa, often in proximity to tropical rainforests [2,3,4]. Epidemiologic investigations could not establish a travel link of reportedly rising cases with endemic areas. Animal hosts of this virus include a range of rodents and non-human primates and transmit to humans with an incubation period of 5 to 21 days. [1]

MPVX is an enveloped double-stranded DNA virus of the Orthopoxvirus genus of the Poxviridae family. [4] It has two distinct genetic clades, namely: the central African (Congo Basin) clade and the west African clade [4]. The Congo Basin clade has historically caused more severe disease and was thought to be more transmissible. The geographical division between the two clades has so far been in Cameroon, the only country where both virus clades have been found [4,5]. The true burden of MPVX cases have been unknown [6]. Since 2017, Nigeria has experienced a large outbreak with over 500 suspected and 200 confirmed cases with a 3% case fatality ratio. [7]

In 2003, the US experienced the first MPVX outbreak of 70 cases beyond Africa, which was linked to animal contact with infected pet prairie dogs [8]. These pets had been housed with Gambian pouched rats and dormice that had been imported into the country from Ghana [8]. Monkeypox has also been reported in travelers from Nigeria to Israel (2018), to United Kingdom (2018, 2019, 2021, 2022), to Singapore (2019), and to the US (2021). In May 2022, multiple cases of monkeypox were identified in several non-endemic countries as mentioned earlier [9]. MPVX infection has become a disease of global public health importance since it is globally spreading in an epidemic proportion.

The recent apparent increase in human MPVX cases across a wide geographic area, the potential for further spread, and the lack of reliable surveillance have heightened the concern for this emerging zoonosis. In November 2017, a collaborative consultation of the World Health Organization (WHO) and CDC with global researchers, global health partners, ministries of health, and orthopoxvirus experts had reviewed and discussed recently detected human MPVX infections in African countries and also identified the surveillance and other improvement measures [10]. Endemic human monkeypox has been reported from more countries in the past decade than during the previous 40 years. Since 2016, confirmed cases of monkeypox have occurred in Central African Republic, Democratic Republic of the Congo, Liberia, Nigeria, Republic of the Congo, and Sierra Leone and in captive chimpanzees in Cameroon [11]. Many countries with endemic monkeypox lack recent experience and specific knowledge about the disease to detect cases, treat patients, and prevent further spread of the virus. Specific improvements in surveillance capacity, laboratory diagnostics, and infection control measures are needed to mount an efficient

response [12]. The recent historic global outbreaks of MPXV following the shocking COVID-19 pandemic have raced scientists to contain it by investigating the change in epidemiology.

Therefore, we aimed to systematically review the current literature on evolutionary epidemiology of emerging human monkeypox virus infection and emphasize on the number of suspected, confirmed, and fatal cases as well as risk factors for contracting monkeypox infection.

Methodology:

Search Strategy:

We performed a systematic review of peer-reviewed literature in accordance with international standards for conducting and reporting systematic reviews including the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Searches were performed on three electronic databases including MEDLINE (accessed using PubMed), Online Willey Library, and Science Direct with no language restrictions. For monkeypox related studies, we included articles from 2018 to 2022 for better comparison.

The search string used the following keywords in all three databases “Orthopox virus” OR “Monkeypox virus” OR “Human Infection” and Transmission of virus to search relevant articles. We aimed to explore how monkeypox epidemiology is evolving including the data related to the number of suspected, confirmed, and fatal cases. We also sought to explore the risk factors for contracting monkeypox infection. We assured that all the data have information such as transmission, pathology and evolution and other features of this virus. Two independent researchers screened the titles and abstracts of the retrieved studies in electronic search and relevant studies were evaluated in full text for eligibility.

Inclusion criteria:

Peer-reviewed articles with complete demographic information and complete medical records of patients who were suffering from monkey pox were included.

Exclusion Criteria:

Non-English studies, letter to editors, posters, cases studies with incomplete information, non-human studies, modelling studies, case reports and articles with unavailable full text were excluded from the review.

Data Extraction

All citations were imported into a bibliographic database and duplicates were removed. Title, abstract and then full text of all articles were screened for eligibility. All the studies which had directly included the MPXV transmission, reported outbreaks as well as sign and symptoms of MPXV were included. The following information was extracted from each study: a) details of the study (study setting, year of publication and study design), b) study population, sample size (male/female) and age in years, c) primary intervention (s) and control group and d) transmission of MPXV. The evaluation of selected data was further done into two phases, first, we selected the data based on abstract and title. Secondly, the full text of the articles was examined and included if they satisfied the eligibility criteria for inclusion.




Fig 1: Inclusion Criteria of selected studies according to PRISMA follow up

Results

The initial search strategy yielded a total of 762 articles, 164 of which were removed due to duplicated articles, and the remaining 598 articles were screened for full-text eligibility. On further screening, we omitted 502 articles with poor information. The remaining 96 articles were further screened for inclusion criteria and 25 articles that fulfilled the inclusion criteria and had adequate data were included. The PRISMA flowchart of the selection process for the systematic review is shown in Figure 1.

Number of reports by country:

Monkeypox data from the DRC accounted for more than one-third of the eligible articles [2,4, 8-11, 17-18, 21-22]. The remaining articles had monkeypox data from the CAR [4, 12, 24-25], Gabon [5, 7], Cameroon [4, 6, 23], ROC [13, 16, 19, 29], Sierra Leone [3, 20], Cote d'Ivoire [3-4], Nigeria [3, 30], and Liberia [3, 31]. (Note: two articles [3-4] described data for more than one country, therefore the total number of articles per country exceeds 25.

Number of cases by country

We identified 25 peer-reviewed articles [1-12, 15-24, 28-30] with data on the number of confirmed cases, number of deaths and case fatality rate (CFR) from human MPXV infection. Since the beginning of 2022, the continent has reported 4,667 cases (559 confirmed; 4,108 suspected) and 127 deaths (CFR: 2.8%) of monkeypox from eight endemic MS: Benin (3 suspected; 3 confirmed; 0 deaths), Cameroon (29; 7; 2), CAR (17; 8; 2), Congo (14; 5; 3), DRC (2,775; 163; 110), Ghana (535; 84; 4), Liberia (31; 2; 0), Nigeria (704; 277; 6) and four non-endemic MS: Egypt (0; 1; 0), Morocco (0; 3; 0), South Africa (0; 5; 0) and Sudan (0; 1; 0). This week, a total of 423 new cases (39 new confirmed; 384 new suspected) and three new deaths of monkeypox were reported from Benin, Congo, Ghana and Liberia.

Table 1. Suspected, confirmed and fatal monkeypox cases by country and year.

[Each box denotes number of probable cases, number of confirmed cases (n), and number of deaths, and/or CFR (%). Where suspect cases were tested and found positive for another disease, these were subtracted from the suspect case total. CFR calculated as number of deaths out of total suspect cases. Grey denotes a period without reported outbreaks. Green denotes locations affected by CB clade. Orange denotes areas affected by WA clade.]

Country	DRC (Zaire 1971-97)*	South Sudan (Sudan pre-2011)	Gabon	Cameroon	CAR	ROC	Sierra Leone	Cote d'Ivoire	Nigeria	Liberia
1970-1974	1970: 1 (1) 100% [2] 1971: 0 1972: 5 1973: 3 1974: 1						1970-71: 1 (1) 0% [3]	10/1971: 1 (U) 0% [3]	1971: 2 (1) 0% [3]	1970-71: 4 (1) 0% [3]
1975-1979	1975: 3 1976: 5 1977: 6 1978: 12 1979: 8			1979: 2 (U) U% [4]					1978: 1 (1) 0% [3]	
1980-1984	1980: 4 1981: 7 1982: 40 1983: 84 1984: 86		1987: Lambarene: 1 (1) 100% □ □ [5]		1984: 6 (U) U% [4]			1981: 1 (U) U% [4]		
1985-1989	1985: 62 1986: 59 [4] 1981-86: 338 (U) 9.8% [4]			1989: 1 (1) 0% [6]						

1990-1994			01/1991-06/1991: Region between Lamberene and N'Djole: 9 (5) 0% [7]						
1995-1999	02/1996-02/1997: Katako-Kombe HZ: 92 (12) 3.3% ^{‡‡} [8] 02/1996 – 10/1997: Kasai Oriental: 511 (U) (1.5%) ^{§§} [9] 03/1997 - 05/1997: Katako-Kombe n=112, Lodja Nord n=58, Sud HZ n=11: 170 (U) 0% (Weekly Epidemiological Record) [10]								
2000** -2004	02/2001-08/2001: Equateur Province: 23 (9) 21.7% [11] 2001: 388 (U) n=13 (3.4%) 2002: 881 (1.6%) 2003: 755 (2.1%) 2004: 1024 (2.8%)				14/08/2001: Pimu CAR/DRC border: 8 cases in a family (U) 25% [12] ^{¶¶}	15/04/03 – 23/06/2003: Likouala department: 12 (3) 8.3% [†] [13]			
2005-2009	2005: 1708 (1.5%) 2006: 783 (2.6%) 2005-7: Sankuru District: 1407 (703) U% [13] 2007: 970 (1.1%) 2008: 1599 (4.2%) 2009: 1919 (1.4%)	10/2005: Unity State: 37 (10) 0% [14]				2007: Likouala department: 62 - 150+ (U) U% [‡] (IRIN, Reliefweb) [15]			

2010-2014	2010: 2322 (1.1%) 2011: 2208 (0.7%) 2012: 2629 (1.3%) 2013: 2460 (1.5%) ^{††} (IDSR data) [16] 2013: Bokungu HZ: 99 (50) 10 (10.1%) [17] [¶]				06/2010: Deep forest, Southern CAR, 480km from DRC border: 2 (2) 0% [§] [11] 30/04/2012: Batangafo: 2 (U) U% [11]	04/10-11/2010: Likouala department: 11 (2) 9.1% [18]	2014: Bo District: 1 (U) U% [19]			
2015-2018	1/1/2016 - 1/3/2016: Ateki HZ: 155 (7) 11 (7.1%) [21] 01/01/2018 - 08/07/2018: IDSR: 2995 (U) 1.2% [22]			30/04/2018: Njikwa Health District: 6 (1) 0% [23]	30/01/2015: Bria: 3 (U) n=1 33% 04/12/2015 - 02/2016: Bakouma and Bangassou subprefectures, Mbomou province: 10 (3) 20% [24] 04/12/2015-28/09/2016: Additional 3 cases reported [□] (IFRC) [25] 04/09/16-07/10/2016: Haute-Kotto health district: 26 (4)	18/01/17 – 15/10/17: Likouala department: 88 (7) 6.8% [29]	14/03/2017: Pujehun district: 1 (1) 0% [20]		2017-18: 24 States: 228 (89) 2.6% [30]	12/2016 1 (U) U% [31]

Table 02. Summary of study findings on monkeypox virus infection outbreaks between 2018 to 2022

Author; Published Year	Objective	Study design	Study population	Outcomes
Nikola et al., 2018	Trace all reported human monkeypox outbreaks and relevant epidemiological information	Systematic review analysis	Congo	urgent need to focus on building surveillance capacities which will provide valuable information for designing appropriate prevention, preparedness and response activities.
Kara et al., 2018	MPX virus as an emerging trend in humans	Review analysis	South Africa	As with all zoonotic diseases, a comprehensive One Health ⁸ approach is necessary for disease detection and response, including wildlife surveillance and investigations into the animal reservoir/reservoirs, which require dedicated resources.
James et al., 2021	Zoonotic orthopoxvirus outbreaks	Review analysis	Middle East and India, buffalopox in India, vaccinia in South America, and novel emerging orthopoxvirus infections in the United States, Europe, Asia, and South America	outbreaks have occurred repeatedly worldwide
Hala et al., 2022	Monkeypox virus: A spreading threat for Pakistan	Review analysis	Pakistan	despite public-health experts declaring Monkeypox a 'containable disease' (unlike COVID-19), the Pakistani government and health ministries must take this matter seriously and adequately prepare for a potential outbreak.

Outbreak investigation of monkeypox virus infection between 2018-2022:

A systemic review and meta-analysis (Nikola et al., 2018) that aimed to study human MPXV outbreaks in Congo showed the urgent need to increase surveillance and preparedness capacity to prevent and control the outbreaks. Another review (Kara et al., 2018) which investigated the emerging trends of MPXV infections in South Africa suggest the need for a one health approach for disease detection as well as wildlife surveillance and investigations into the animal reservoir/reservoirs. [Table 2]

Mode of transmission and risk factors:

In DRC, sleeping in the same floor was significantly (odds ratio [OR] 6.1, 95% confidence interval [CI] 1.2-31.6) associated with contracting MPVX while eating or processing animal foods was not a significant risk factor. In United States, cleaning cages and bedding a sick animal (OR 5.3, 95% CI 1.4-20.7), or touched an infected animal (OR 4.0, 95% CI 1.2-13.4), daily direct or indirect sick animal exposure (OR 4.0, 95% CI 1.2-13.4) were associated with contracting MPVX infection. [Table 3]

Table 03. Summary of study findings on risk factors for primary introduction of monkeypox.

Country	Risk Factor	OR	aOR for vaccination status (95% CI)	P Value	Number of cases, n (Number of controls, n)
DRC [2]*	Vaccinated	0.1 (0.03, 0.6)	NA	ND	252 (653)
	Exposure to Gambian rats	ND	2.6 (1.6, 4.1)	ND	
	Large terrestrial rodents	ND	1.8 (1.1, 3.0)	ND	
	Prosimians	ND	1.9 (1.2, 2.8)	ND	
	Non-human primates	ND	2.7 (1.4, 4.9)	ND	
DRC [3]	Live in house with a door	0.07 (0.01, 0.6)	ND	0.01	15 (50)
	Prepared wild animal for consumption	0.2 (0.09, 0.1)	ND	0.04	
	Ate duiker	0.15 (0.03, 0.7)	ND	0.01	
	Sleep on floor	6.1 (1.2, 31.6)	ND	0.03	
USA [4]	Vaccinated	0.3 (0.1, 0.9)	NA	ND	30 (35) [†]
	Touched an infected animal	3.8 (1.2–11.7)	4.0 (1.2, 13.4)	ND	
	Cleaned the cage or touched the bedding of an infected animal	5.3 (1.5, 18.9)	5.3 (1.4, 20.7)	ND	
	Received scratch from infected animal	5.6 (1.1, 28.6)	3.9 (0.7, 21.1)	ND	
	Daily indirect or direct exposure to an ill animal was significantly associated with MPX developing	3.8 (1.2, 11.7)	4.0 (1.2, 13.4)	ND	
	Having come within 6 feet but not touched by an infected animal	2.0 (0.6, 6.2)	2.0 (0.6, 6.5)	ND	

NA = Not applicable ND = Not Described *Conference abstract, no methodology provided [†]Three controls were found to have elevated levels of IgM to orthopoxvirus.

DISCUSSION

This systematic review provides a comprehensive review of the epidemiologic evolution of MPXV infection since its first human detection in 1970s. We found a greater than 14-fold increase in confirmed MPXV cases over the past 5 decades, from 55 cases in the 1970s to 793 cases in the 1990s, with DRC being the most affected country. As a result of the recent outbreak, the number of confirmed cases in Nigeria has escalated from 3 cases in the 1970s to 341 cases in 2015–2018. There is a growing concern regarding the geographical spread and re-emergence of MPXV. In last five decades, the outbreaks have been reported in 10 African countries. Concerningly, the re-emergence of MPXV occurred in Nigeria, Liberia, and Sierra Leone after 40 years and in the CAR after 30 years. We report a rapid rise of MPVX cases in a highly endemic DRC after 1970s while spreading to other countries. Cessation of smallpox vaccination might be one of the factors responsible for the findings.

Monkeypox typically transmits to humans from wild animals, such as rodents and primates (animals-to-humans), or in some cases, from other infected individuals (humans-to-humans) [4, 36]. Nine studies showed the source of infection was sexual contact, especially with male partners. Six studies mentioned the cause of infection was contact with an individual with monkeypox symptoms. Two studies considered cases due to acquired nosocomial infection. Ingestion of barbecued bushmeat was the source of infection in three studies and rodent carcasses were the source of infection in the other two studies [40]. The opportunistic infection predominantly spreads through contact, such as hunting or consuming disease-ridden animals [4, 36]. It can also spread through large aerosol droplets or contact with body fluids (saliva and blood), infected skin lesions, or contaminated materials, such as the clothing of an infected individual [4, 37]. Following an incubation period of 5–21 days, the virus clinically manifests as fever, headache, myalgia, lymphadenopathy, and fatigue, similar to the presentation of the smallpox infection [4,37]. Individuals infected with a more barbaric form of the disease may also develop a characteristic ‘*Monkeypox rash*’, starting from their face and hands and later spreading to other body parts [5,38]. The lesions which typically start as macules progress into papules, followed by fluid-filled vesicles, pus-filled pustules, and subsequently, scabs that crust and eventually fall off [5,38]. The disease is often self-limiting, with the symptoms eventually resolving within 2–4 weeks. As supported by historical data, the smallpox vaccine (Imvanex) is 85% effective against Monkeypox. Similarly, antivirals, including Tecovirimat, Cidofovir, and Vaccinia Immune Globulin Intravenous (VIGIV) approved for smallpox infection, can also be used for Monkeypox treatment [36,37].

Due to the atypical disease presentation and transmission patterns, the recent MPXV surge is “rare and unusual” compared to earlier outbreaks. [36,37] As reported by health experts, most of the Monkeypox cases recorded in the past month in the Western Hemisphere have no known epidemiological links to endemic countries [37]. Additionally, most of the cases were documented among young men engaging in homosexual or bisexual activities, commonly known as “men who have sex with men” (MSM) [37]. Most of these cases presented with genital or peri-genital lesions, indicating a new route of disease spread, sexual contact. Although a definite cause for the sudden upsurge in cases is yet to be determined, health experts worldwide have suggested several theories which are currently under investigation. Till 2022 genomic sequences of ten MPXV strains, associated with the recent countrywide outbreak, have been determined. While West African Clade is mostly implicated in the recent viral surge, data were insufficient to determine which mutation contributed to increased transmissibility [38,39]. We found that in DRC, sleeping on the floor was significantly associated with contracting MPXV while eating or processing animal foods was not a

significant risk factor. In the United States, cleaning cages, bedding sick animals, or touching infected animals, daily sick animal exposure was associated with contracting MPVX infection.

Health officials stopped recommending smallpox inoculation following the eradication of smallpox in the late nineties [36,37]. Given that smallpox and Monkeypox viruses belong to the same genus (Orthopoxvirus), the cessation of the smallpox vaccine resulted in populations developing a weakened immunity to MPXV [37]. The waning immunity against the virus over several years served as a nidus for infection, resulting in the latest re-surge. almost five decades ago, MPXV was considered a “disease of young children”, predominately affecting children aged 4–5 years [37]. By the 2000s, this number had increased five times, with ages 20–25 years old being most vulnerable to infection [38,39]. This is in line with the current data, which suggests that most of the recently reported MPXV cases have been in young men. It is highly likely that most of these individuals were not administered the smallpox vaccine either because they were too young or were born after the termination of routine vaccination.

The resumption of everyday life following the Coronavirus-2019 (COVID-19) pandemic can also be attributed as a factor favoring MPXV spread. With the lifting of travel restrictions coupled with the easing of social distancing measures, individuals were more likely to have been in close physical contact, thereby encouraging viral transmission. Moreover, the decline in the number of dendritic cells, and consequently the wearying immune system response post-COVID-19 infection, results in recovered individuals being more vulnerable to secondary infections; the Monkeypox re-surge might be just another testament to this fact.

Conclusion

Recent global outbreaks, the rising incidence in young adults and endemic zones might result from smallpox vaccine cessation. Increased risk with sick animal exposure or sleeping on the floor suggests high infectivity from animal excretions. Increasing awareness, strict surveillance, and contact tracing can contain global outbreaks. Ring vaccination approach to exposed people can also be a strategy. Future studies should investigate to determine measures for rapid laboratory diagnosis, maintaining lab safety, and also transmissibility. In addition, given that diagnosing MPXV infection based on their symptoms is not a reliable approach, it is imperative that the WHO urgently procures the required testing kits, primers, and reagents to combat a possible viral epidemic.

Recommendations

Raising awareness among healthcare providers and the general population, implementing strict surveillance measures and timely contact tracing (in case of a viral outbreak) are the best preventative measures to effectively prevent or manage a potential Monkeypox outbreak in the country. Per expert-issued guidelines, mass smallpox vaccination campaigns are not a requirement. Instead, a ring vaccination approach needs to be utilized, that is, to only vaccinate people in close contact with infected individuals. This way the challenges presented due to the limited global supply of smallpox vaccine and the prevalent vaccination hesitancy in the world can be overcome, albeit to some extent.

Acknowledgments

Not applicable.

Funding

Not Applicable

Declarations

Ethics approval and consent to participate not applicable.

Conflicts of interest

The authors declare no conflicts of interest.

Author Contributions

Sunder Sham: Study design, collecting data, data analysis, and manuscript writing.

FNU Sapna, Sanjay Kumar, Anjali, Ahmed Bandari, Reham Al-Refai, Mohammed Abdelwahed, Manal Mohammad Baloch, Soumya Jaladi, FNU Kiran and Hansini Laharwani, and data collection and analysis

Vivek Podder: review and editing

All the authors have read and approved the final manuscript.

References

1. Ntoumi F, Zumla A. Advancing accurate metrics for future pandemic preparedness. *The Lancet*. 2022 Apr 16;399(10334):1443-5.
2. Hoff N, Mulembakani PM, Johnston SC, Kisalu NK, Muyembe JJ, Hensley LE, et al. Risk factors associated with human monkeypox in the democratic republic of Congo. *American Journal of Tropical Medicine and Hygiene*. 2014;1):199-200.
3. Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B, et al. Introduction of Monkeypox into a Community and Household: Risk Factors and Zoonotic Reservoirs in the Democratic Republic of the Congo. *American Journal of Tropical Medicine & Hygiene*. 2015;93(2):410-5.
4. Reynolds MG, Davidson WB, Curns AT, Conover CS, Huhn G, Davis JP, et al. Spectrum of infection and risk factors for human monkeypox, United States, 2003. *Emerging Infectious Diseases*. 2007;13(9):1332-9.
5. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. *Bulletin of the World Health Organization*. 1972;46(5):593-7.
6. Breman JG, Kalisa R, Steniowski MV, Zanotto E, Gromyko AI, Arita I. Human monkeypox, 1970-79. *Bulletin of the World Health Organization*. 1980;58(2):165-82.
7. Jezek ZaF, F. Human monkeypox. *Monographs in Virology*. Karger, editor. Basel 1988.
8. Muller G, Meyer A, Gras F, Emmerich P, Kolakowski T, Esposito JJ. Monkeypox virus in liver and spleen of child in Gabon. *Lancet*. 1988;1(8588):769-70.
9. Tchokoteu PF, Kago I, Tetanye E, Ndoumbe P, Pignon D, Mbede J. [Variola or a severe case of varicella? A case of human variola due to monkeypox virus in a child from the Cameroon]. *Ann Soc Belg Med Trop*. 1991;71(2):123-8.
10. Record. WE. Monkeypox, 1991. Gabon. *Weekly Epidemiological Record*. 1992;67(14):101-2.
11. Record. WE. Monkeypox in the Democratic Republic of the Congo (former Zaire). *Weekly Epidemiological Record*. 1997;72(34):258.
12. Mukinda VB, Mwema G, Kilundu M, Heymann DL, Khan AS, Esposito JJ. Re-emergence of human monkeypox in Zaire in 1996. *Monkeypox Epidemiologic Working Group. Lancet*. 1997;349(9063):1449-50.
13. Prevention. CfDca. Human monkeypox -- Kasai Oriental, Democratic Republic of Congo, February 1996-October 1997. *MMWR - Morbidity & Mortality Weekly Report*. 1997;46(49):1168-71.
14. Meyer H, Perrichot M, Stemmler M, Emmerich P, Schmitz H, Varaine F, et al. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. *Journal of Clinical Microbiology*. 2002;40(8):2919-21.
15. Berthet N, Nakoune E, Whist E, Selekon B, Burguire AM, Manuguerra JC, et al. Maculopapular lesions in the Central African Republic. *The Lancet*. 2011;378(9799):1354.
16. Learned LA, Reynolds MG, Wasswa DW, Li Y, Olson VA, Karem K, et al. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. *American Journal of Tropical Medicine & Hygiene*. 2005;73(2):428-34.

17. McMullen CL, Mulembekani P, Hoff NA, Doshi RH, Mukadi P, Shongo R, et al. Human monkeypox transmission dynamics thirty years after smallpox eradication in the Sankuru district, democratic republic of Congo. *American Journal of Tropical Medicine and Hygiene*. 2015;93 (4 Supplement):341.
18. Formenty P, Muntasir MO, Damon I, Chowdhary V, Opoka ML, Monimart C, et al. Human monkeypox outbreak caused by novel virus belonging to Congo Basin clade, Sudan, 2005. *Emerging Infectious Diseases*. 2010;16(10):1539-45.
19. Congo: Monkeypox infects 60 in North [Internet]. Reliefweb: Reliefweb; 2007; 25/09/2007
20. Hoff NA, Kebela-Ilunga B, Eckhoff P, Mukadi P, Mossoko M, Muyembe-Tamfum JJ, et al. A descriptive and quantitative analysis of potential underestimation of human monkeypox cases in the passive surveillance system in the democratic republic of congo. *American Journal of Tropical Medicine and Hygiene*. 2015;93 (4 Supplement):242.
21. Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B, et al. Extended human-to-human transmission during a monkeypox outbreak in the Democratic Republic of the Congo. *Emerging Infectious Diseases*. 2016;22(6):1014-21.
22. Reynolds MG, Emerson GL, Pukuta E, Karhemere S, Muyembe JJ, Bikindou A, et al. Short report: Detection of human monkeypox in the Republic of the Congo following intensive community education. *American Journal of Tropical Medicine and Hygiene*. 2013;88(5):982-5.
23. WHO. WHO AFRO Outbreaks and Other Emergencies, Week 16: 15 – 21 April 2017 Data as reported by 17:00 21 April 2017. Reliefweb: 2017.
24. Laudisoit A. Bushmeat and Monkeypox: Yahuma Health Zone – Aketi Health Zone - Bombongolo Health Area. Kisangani, DRC.: CIFOR, Université de Kisangani, DRC., 2016.
25. Nakoune E, Selekon B, Komoyo GF, Kazanji M, Garba-Ouangole SM, Janssens C, et al. A Nosocomial Outbreak of Human Monkeypox in the Central African Republic. *Open Forum Infectious Diseases*. 2017;4(4).
26. IFRC. Central African Republic: Monkey Pox Outbreak - Dec 2015. Reliefweb: 2016.
27. WHO. Monkeypox in Central African Republic. Reliefweb: 2016.
28. Kalthan E, Tenguere J, Ndjapou SG, Koyazengbe TA, Mbomba J, Marada RM, et al. Investigation of an outbreak of monkeypox in an area occupied by armed groups, Central African Republic. *Medecine et Maladies Infectieuses*. 2018;48(4):263-8.
29. WHO. WHO AFRO Outbreaks and Other Emergencies, Week 13: 25 – 31 March 2017 Data as reported by 17:00 31 March. . Reliefweb: 2017.
30. WHO. WHO AFRO Outbreaks and Other Emergencies, Week 48: 25 November - 01 December 2017 (Data as reported by 17:00; 1 December 2017). Reliefweb: 2017.
31. NCDC. Situation Report: Monkeypox Outbreak in Nigeria. Abuja: 2018.
32. ISDR. L. Liberia IDSR Epidemiology Bulletin 2016 Epi Week 51 (December 16 – December 22). Reliefweb: 2016.
33. SDR. L. Liberia IDSR Epidemiology Bulletin 2017 Epi Week 19 (May 8 –14, 2017). Reliefweb: 2017.
34. ISDR. L. Liberia IDSR Epidemiology Bulletin 2017 Epi Week 49 (December 4 – December 10). Reliefweb: 2017.
35. Najeeb H, Huda Z. Monkeypox virus: A spreading threat for Pakistan? *Ann Med Surg (Lond)*. 2022 Jun 11;79:103977.
36. Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. *PLoS Negl Trop Dis*. 2019 Oct 16;13(10):e0007791.

37. Quarleri J, Delpino MV, Galvan V. Monkeypox: considerations for the understanding and containment of the current outbreak in non-endemic countries. *Geroscience*. 2022 Jun 20:1–9.
38. Adnan N, ul Haq Z, Malik A, Mehmood A, Ishaq U, Faraz M, Malik J, Mehmoodi A. Human monkeypox virus: An updated review. *Medicine*. 2022 Sep 2;101(35):e30406.
39. Sklenovská N, Van Ranst M. Emergence of Monkeypox as the Most Important Orthopoxvirus Infection in Humans. *Front Public Health*. 2018 Sep 4;6:241.
40. Ghazy RM, Hammad EM, Hall MA, et al. How can imported monkeypox break the borders? A rapid systematic review. *Comp Immunol Microbiol Infect Dis*. 2023;92:101923. doi:10.1016/j.cimid.2022.101923